News | August 27, 2024
Mangalam Drugs & Organics awarded US$ 274,800 grant by MMV
The grant is designated for the research and development of Pyronaridine
The grant is designated for the research and development of Pyronaridine
This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
Innovative technologies and comprehensive services to strengthen Syntegon’s strategic growth
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
Subscribe To Our Newsletter & Stay Updated
